

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumension Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1477)**

**VOLUNTARY ANNOUNCEMENT**  
**COOPERATION WITH VIATRIS ON DISTRIBUTION AND**  
**PROMOTION OF OPHTHALMIC DRUGS**

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

**COOPERATION WITH VIATRIS**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on March 1, 2022, the Group entered into a series of cooperation arrangements with Viatriis Pharmaceuticals Co., Ltd. (暉致醫藥有限公司) (“**Viatriis China**”, a Chinese affiliate of Viatriis Inc., a corporation incorporated and existing under the laws of the Delaware, the United States, with the business address at 1000 Mylan Boulevard, Canonsburg, PA 15317. Viatriis Inc., together with its affiliates, are collectively referred to as “**Viatriis**”), pursuant to which the Group became the exclusive promoter to promote and market in hospitals nationwide in the People’s Republic of China (the “**PRC**”, exclusively for the purpose of this cooperation, not including Hong Kong SAR, Macau SAR and Taiwan) two ophthalmic drugs of Viatriis, namely Xalatan (適利達) and Xalacom (適利加), further information of which is set out below, and will charge Viatriis China promotion service fees. The initial term of the promotion arrangement is from March 1, 2022 to December 31, 2026, with conditional automatic renewal. Reciprocally, Viatriis China became the exclusive distributor to distribute, promote and market the Company’s sodium hyaluronate eye drops (玻璃酸鈉滴眼液) in the out-of-hospital distribution and retail drug markets in the PRC, and will charge the Group relevant fees during a period. The initial term of the distribution arrangement is from March 1, 2022 to December 31, 2026, with conditional automatic renewal. Other than the fees aforementioned, no other fees or charges will be incurred by both parties under the cooperation arrangements.

## **REASONS AND BENEFITS OF THE COOPERATION**

The Company believes that cooperation arrangements with Viartis China will be able to capture certain synergetic effects brought along by the cooperation in terms of business development in the PRC. By collaborating with Viartis China, the Group obtained the promotion rights of current first-line drug for glaucoma and intraocular pressure lowering treatment in hospitals nationwide in the PRC, and thus to expand its pipeline and thereby enhancing the Group's overall sales performance and improving its sales coverage in public hospitals in the PRC. In addition, Viartis is a well-recognized and world-renowned pharmaceutical corporation. The Company believes that, with the boost of strong retail promotion capabilities of Viartis China, including but not limited to market penetration and various sales channels, it will further facilitate the Group's market expansion and enhance its brand recognition; also, the cooperation arrangements with Viartis China will further enable the Group establishing a long-term and stable cooperative relationship with such world-renowned pharmaceutical corporation and will be beneficial to the Company's business layout in the future.

## **INFORMATION OF THE PRODUCTS**

### **Sodium hyaluronate eye drops (玻璃酸钠滴眼液)**

Sodium hyaluronate eye drops are approved by National Medical Products Administration of the PRC for the treatment of dry eye. Hyaluronic acid is naturally produced by the human body to keep tissues well lubricated and moist. Sodium hyaluronate eye drops have a unique dosage form of 0.3% concentration in 0.8 ml single-dose packaging currently, and they have a potentially better safety profile because they do not contain preservatives and therefore have no corneal toxicity.

### **Xalatan (適利達)**

Latanoprost eye drops, sold under the brand name Xalatan, are used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Latanoprost is in a class of medications called prostaglandin analogs. It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye.

### **Xalacom (適利加)**

Xalacom is a combination of an ophthalmic prostaglandin drug (latanoprost) and an ophthalmic beta-blocking drug (Timolol Maleste), both of which lower the pressure within the eye in different ways. The prostaglandin drug works by increasing the natural outflow of fluid from inside the eye. The betablocking drug works by decreasing the fluid production in the eye. Xalacom is used to reduce intraocular pressure in patients with open angle glaucoma or ocular hypertension. Both these conditions are related to an increase in pressure within the eye and eventually may affect eyesight.

## INFORMATION OF THE PARTIES

### About Viatriis

Viatriis Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. Viatriis provides access to medicines, advance sustainable operations, develop innovative solutions and leverage its collective expertise to connect more people to more products and services through its one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatriis brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatriis' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 38,000, Viatriis is headquartered in the United States, with global centers in Pittsburgh, Pennsylvania, the United States, Shanghai, the PRC and Hyderabad, India.

### About Ocumension Therapeutics

The Group is an ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. The Group has a portfolio of 20 drug assets, covering all major front- and back-of-the-eye diseases, among which six key drug candidates are in phase III clinical trial stage.

To the best of the Company's knowledge, information and belief, and having made all reasonable enquiries, Viatriis China and their ultimate beneficial owners are all third parties independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on the Stock Exchange).

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, March 1, 2022

*As of the date of this announcement, the board of directors of the Company comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive directors.*